Neurology Department

The Department of Neurology of Tianjin Medical University General Hospital is a well-known neurological diagnosis and treatment center in Tianjin and even across the country. It integrates clinical practice, scientific research and teaching, and is committed to the comprehensive clinical diagnosis, treatment and research of various diseases such as cerebrovascular diseases, nervous system autoimmune diseases, epilepsy and nervous system degenerative diseases.

It has 160 inpatient beds in 4 wards, an 8-bed intensive care unit (NICU), and 8 clinical service platforms with no holiday outpatient and emergency services. The annual outpatient volume is 210,000, and the number of discharged patients exceeds 4,500 annually.

It also has a professional laboratory research platform (Institute of Neurology) with an area of ​​5,400 m2 covering four research directions: neuroimmunity, neurobiochemistry, neuroelectrophysiology and epidemiology.

The available funding for national-level projects exceeds 40 million yuan.

The medical teaching and research team has rich human resources and a reasonable personnel structure.

Every year, it trains about 50 graduates with doctoral and master's degrees and advanced students, and nearly 100 overseas internship and trainee students.

They strive to provide patients with high-level professional clinical services.

For patients with early ischemic stroke, standardized antithrombotic treatment should be adopted while timely improvement of examination, evaluation and interventional treatment of extracranial and intracranial blood vessels.

He has accumulated rich experience and achieved many results in the diagnosis and treatment of demyelinating diseases of the central nervous system. In particular, he was the first in China to use low-dose rituximab to perform immunomodification therapy on patients with neuromyelitis optica, with remarkable results. He was the first to carry out immunotherapy with betaerone and Libi for multiple sclerosis in Tianjin, and discovered cell markers for the responsiveness of myasthenia gravis patients to immunomodulatory drugs.

Taking advantage of the hospital's combined neurosurgical and neurosurgical treatment capabilities, we provide specialized treatment for patients with epilepsy and Parkinson's disease, and gradually improve the screening of patients with dementia and Parkinson's disease.

At the same time, as one of the first batch of clinical drug observation and research institutions in the country, it has 20 years of experience in clinical new drug experimental observation.

The department will always focus on clinical services, take Tianjin as its foothold, and serve the whole country, making unremitting efforts to relieve the pain of the majority of patients.